Research

Hormonal

Tirzepatide reduces the incidence of heart failure hospitalizations, need for treatment intensification, and mortality due to cardiovascular causes in patients with heart failure and reduced ejection fraction.

If you have heart failure and reduced ejection fraction, Tirzepatide can reduce your risk of hospitalization and cardiovascular mortality.

GoodSupportsHIGH confidence
At the end of 52 weeks, there was a 38% lower incidence of heart failure hospitalizations, need for treatment intensification, and lower mortality due to cardiovascular causes.
Andrés Calderón et al. · Methodist DeBakey Cardiovascular Journal · 2025

Why this rating

Based on the SUMMIT trial.

Source

Medical Management of Obesity: Current Trends and Future Perspectives

Andrés Calderón et al. · Methodist DeBakey Cardiovascular Journal · 2025

DOI 10.14797/mdcvj.1503

narrative_reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →